Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

OPTImal PHARMacological therapy for patients with heart failure: Rationale and design of the OPTIPHARM-HF registry.

Title: OPTImal PHARMacological therapy for patients with heart failure: Rationale and design of the OPTIPHARM-HF registry.
Authors: Inciardi, RM; Vaduganathan, M; Lombardi, CM; Gussago, C; Agostoni, P; Ameri, P; Aspromonte, N; Calò, L; Cameli, M; Carluccio, E; Carugo, S; Cipriani, M; De Caterina, R; De Ferrari, GM; Emdin, M; Fornaro, A; Guazzi, M; Iacoviello, M; Imazio, M; La Rovere, MT; Leonardi, S; Maccallini, M; Masarone, D; Moschini, L; Palazzuoli, A; Patti, G; Pedretti, RFE; Perrone Filardi, P; Piepoli, MF; Potena, L; Salzano, A; Sciacqua, A; Senni, M; Sinagra, G; Specchia, C; Taddei, S; Vizza, D; Savarese, G; Rosano, G; Volterrani, M; Metra, M; on behalf of the OPTIPHARM‐HF investigators
Publisher Information: Wiley
Publication Year: 2024
Collection: St George's University of London: Repository
Description: AIMS: Patients with heart failure (HF) remain often undertreated for multiple reasons, including treatment inertia, contraindications, and intolerance. The OPTIimal PHARMacological therapy for patients with Heart Failure (OPTIPHARM-HF) registry is designed to evaluate the prevalence of evidence-based medical treatment prescription and titration, as well as the causes of its underuse, in a broad real-world population of consecutive patients with HF across the whole ejection fraction spectrum and among different clinical phenotypes. METHODS: The OPTIPHARM-HF registry (NCT06192524) is a prospective, multicenter, observational, national study of adult patients with symptomatic HF, as defined by current international guidelines, regardless of ejection fraction. Both outpatients and inpatients with chronic and acute decompensated HF will be recruited. The study will enroll up to 2500 patients with chronic HF at approximately 35 Italian HF centres. Patients will be followed for a maximum duration of 24 months. The primary objective of the OPTIPHARM-HF registry is to assess prescription and adherence to evidence-based guideline-directed medical therapy (GDMT) in patients with HF. The primary outcome is to describe the prevalence of GDMT use according to target guideline recommendation. Secondary objectives include implementation of comorbidity treatment, evaluation of sequence of treatment introduction and up-titration, description of GDMT implementation in the specific HF population, main causes of GDMT underuse, and assessment of cumulative rate of cardiovascular events. CONCLUSION: The OPTIPHARM-HF registry will provide important implications for improving patient care and adoption of recommended medical therapy into clinical practice among HF patients.
Document Type: article in journal/newspaper
File Description: application/pdf
Language: English
ISSN: 1879-0844
Relation: https://openaccess.sgul.ac.uk/id/eprint/116739/1/European%20J%20of%20Heart%20Fail%20-%202024%20-%20Inciardi%20-%20OPTImal%20PHARMacological%20therapy%20for%20patients%20with%20heart%20failure%20%20Rationale%20and.pdf; Inciardi, RM; Vaduganathan, M; Lombardi, CM; Gussago, C; Agostoni, P; Ameri, P; Aspromonte, N; Calò, L; Cameli, M; Carluccio, E; et al. Inciardi, RM; Vaduganathan, M; Lombardi, CM; Gussago, C; Agostoni, P; Ameri, P; Aspromonte, N; Calò, L; Cameli, M; Carluccio, E; Carugo, S; Cipriani, M; De Caterina, R; De Ferrari, GM; Emdin, M; Fornaro, A; Guazzi, M; Iacoviello, M; Imazio, M; La Rovere, MT; Leonardi, S; Maccallini, M; Masarone, D; Moschini, L; Palazzuoli, A; Patti, G; Pedretti, RFE; Perrone Filardi, P; Piepoli, MF; Potena, L; Salzano, A; Sciacqua, A; Senni, M; Sinagra, G; Specchia, C; Taddei, S; Vizza, D; Savarese, G; Rosano, G; Volterrani, M; Metra, M; on behalf of the OPTIPHARM‐HF investigators (2024) OPTImal PHARMacological therapy for patients with heart failure: Rationale and design of the OPTIPHARM-HF registry. Eur J Heart Fail, 26 (8). pp. 1707-1714. ISSN 1879-0844 https://doi.org/10.1002/ejhf.3260 SGUL Authors: Rosano, Giuseppe Massimo Claudio
DOI: 10.1002/ejhf.3260
Availability: https://openaccess.sgul.ac.uk/id/eprint/116739/; https://doi.org/10.1002/ejhf.3260
Rights: cc_by_nc_nd_4
Accession Number: edsbas.AFF18B5D
Database: BASE